Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.83 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.83 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.83 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.83 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.66 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410553 | 0.93 | MAPK13 (0.75) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL12245433 | 0.91 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3300214 | 0.90 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL938408 | 0.88 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL12245434 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL16866510 | 0.86 | MAPK13 (0.83) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5733448 | 0.85 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL16866512 | 0.85 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL28933401 | 0.85 | MAPK13 (0.85) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14039599 | 0.84 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056725-B1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-07 | — | — | EP | claimed |
| US-7625915-B2 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | BAYER HEALTHCARE LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080300281-A1 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas | DUMAS JACQUES | 2008-12-04 | — | — | US | disclosed |
| EP-1043995-B9 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7329670-B1 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080009527-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2008-01-10 | — | — | US | disclosed |
| EP-1043995-B1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1056725-B1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1043995-A4 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1056725-A4 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | disclosed |
| CN-1283192-A | Inhibition of raf kinase using aryl and hetroaryl substituted heterocyclic ureas | BAYER AG (US) | 2001-02-07 | — | — | CN | disclosed |
| EP-1056725-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1043995-A1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999032110-A1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032455-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300281-A1 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas | MAPK1, MAP3K1, MAP3K2 | MAPK14 31/4885MAPK13 35/4885MAPK12 42/4885 |
| US-20080009527-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | MAPK14 166/4885MAPK13 92/4885MAPK12 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.